Encouraging incremental data by Canadians at ASCO

Dundee Securities summed up some of the Canadian data presented at this year’s clinical oncology conference by AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ), OncoGenex (NASDAQ:OGXI), Tekmira (TSX:TKM) and MethylGene (TSX:MYG) as “encouraging, but mainly incremental.” Nevertheless, analyst David Martin downgraded MethylGene to “neutral” from “buy,” without a price target. While he called data from the company’s MGCD265 [...]

AEterna’s missed Phase 3 gets ho-hum analyst reaction

Analysts are not surprised that Aeterna Zentaris’ cetrorelix drug candidate missed its primary endpoint in a Phase 3 clinical trial in Europe, matching the disappointing outcome of a similar pivotal trial in the U.S. earlier this year. RBC Capital Markets now expects AEterna (NASDAQ:AEZS; TSX:AEZ) to terminate the cetrorelix program and focus on its other [...]